



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

Investor Contact:

GenVec, Inc.
Danielle M. DiPirro
(301) 944-1877
ddipirro@genvec.com

Media Contact:

Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020
amielach@tiberendstrategicadvisors.com

**GENVEC TO HOST FOURTH QUARTER AND YEAR-END
2009 EARNINGS CALL AND WEBCAST**

GAITHERSBURG, MD – March 5, 2010 – GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the fourth quarter and year ended December 31, 2009 on Thursday, March 11, 2010 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, March 12, 2010 to discuss the company’s 2009 financial results and 2010 business outlook.

To listen to the live conference call, please dial 888.679.8034 (U.S. or Canada) or 617.213.4847 (international) and use access code 78294324. Participants may pre-register for the call anytime at: <https://www.theconferencingservice.com/prereg/key.process?key=P98VGYDNM>. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 12:00 p.m. on March 12, 2010 through March 19, 2010. To listen to the audio replay, dial 888.286.8010 (U.S. or Canada) or 617.801.6888 (international) and use access code 55380218.

A live webcast of the conference call will be available on the Company’s website will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on “Investor Relations,” and click on “Webcasts and Data.”

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with

Novartis. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

###